MediciNova, Inc. (MNOV)
NASDAQ: MNOV · Real-Time Price · USD
1.260
+0.035 (2.86%)
Oct 10, 2025, 10:57 AM EDT - Market open
MediciNova Revenue
MediciNova had revenue of $134.60K in the quarter ending June 30, 2025.
Revenue (ttm)
$134.60K
Revenue Growth
-86.54%
P/S Ratio
446.38
Revenue / Employee
$10,354
Employees
13
Market Cap
61.80M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 1.00M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 4.04M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | 6.00M | 5.20M | 647.99% |
| Dec 31, 2012 | 802.58K | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
| Dec 31, 2006 | 263.88K | -540.19K | -67.18% |
| Dec 31, 2005 | 804.07K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
MNOV News
- 4 days ago - MediciNova to Present at the LD Micro Main Event XIX Investor Conference - GlobeNewsWire
- 4 weeks ago - MediciNova Provides Shareholder Update on Key Developments - GlobeNewsWire
- 5 weeks ago - MediciNova to Present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 6 weeks ago - MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial - GlobeNewsWire
- 2 months ago - MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million - GlobeNewsWire
- 2 months ago - MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials - GlobeNewsWire
- 6 months ago - MediciNova To Participate in D. Boral's Capital Global Conference on May 14, 2025 - GlobeNewsWire
- 6 months ago - First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients - GlobeNewsWire